III期临床试验-话题@MedSci

#III期临床试验#

101篇内容 | 2156人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1588050, encodeId=18d3158805027, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=75, createdTime=2020-05-19, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588049, encodeId=d82515880491e, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, objectType=article, longId=193525, objectId=9a4819352542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a4819352542, replyNumber=0, likeNumber=75, createdTime=2020-05-06, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a4819352542, moduleTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a4819352542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588048, encodeId=a1d7158804863, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, objectType=article, longId=192391, objectId=50af192391d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50af192391d8, replyNumber=0, likeNumber=72, createdTime=2020-04-18, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50af192391d8, moduleTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50af192391d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588047, encodeId=6771158804e9f, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=71, createdTime=2020-04-11, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588046, encodeId=b91f1588046b9, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, objectType=article, longId=190723, objectId=c191190e23e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c191190e23e2, replyNumber=0, likeNumber=106, createdTime=2020-03-26, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c191190e23e2, moduleTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c191190e23e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588045, encodeId=cfbe15880451e, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, objectType=article, longId=190693, objectId=7c61190693ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c61190693ac, replyNumber=0, likeNumber=38, createdTime=2020-03-25, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c61190693ac, moduleTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c61190693ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588044, encodeId=1966158804426, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=0, createdTime=2020-03-07, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588043, encodeId=135e158804315, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, objectType=article, longId=187677, objectId=e89218e67760, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e89218e67760, replyNumber=0, likeNumber=38, createdTime=2020-02-09, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e89218e67760, moduleTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e89218e67760)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588042, encodeId=97a5158804222, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, objectType=article, longId=187585, objectId=d55418e58511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55418e58511, replyNumber=0, likeNumber=60, createdTime=2020-02-08, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55418e58511, moduleTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d55418e58511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588041, encodeId=015c158804169, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=43, createdTime=2020-01-02, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588040, encodeId=ba06158804095, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=35, createdTime=2020-01-01, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588039, encodeId=5cba1588039fa, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, objectType=article, longId=185186, objectId=397c185186ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397c185186ea, replyNumber=0, likeNumber=35, createdTime=2019-12-26, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397c185186ea, moduleTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397c185186ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588038, encodeId=4eac15880380a, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=33, createdTime=2019-12-22, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588037, encodeId=201b158803e22, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, objectType=article, longId=184569, objectId=5a93184569d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a93184569d3, replyNumber=0, likeNumber=36, createdTime=2019-12-13, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a93184569d3, moduleTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a93184569d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588036, encodeId=b4b11588036d5, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, objectType=article, longId=181869, objectId=b55d181869fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55d181869fc, replyNumber=0, likeNumber=41, createdTime=2019-10-26, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55d181869fc, moduleTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55d181869fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588035, encodeId=fb361588035f2, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=76, createdTime=2019-08-17, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588034, encodeId=9984158803411, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=0, createdTime=2019-08-12, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588033, encodeId=c6b915880338b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=84, createdTime=2019-08-11, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588032, encodeId=07ba1588032eb, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=37, createdTime=2019-07-03, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588031, encodeId=77d8158803149, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=42, createdTime=2019-06-29, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期临床试验

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-05-19

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始

2020-05-06

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组

2020-04-18

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2020-04-11

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

2020-03-26

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展

2020-03-25

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-03-07

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果

2020-02-09

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册

2020-02-08

heli0118 (审核中...)

前往app查看评论内容

#III期临床试验#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-01-02

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-01-01

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验

2019-12-26

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2019-12-22

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果

2019-12-13

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始

2019-10-26

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-08-17

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2019-08-12

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2019-08-11

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2019-07-03

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-06-29

科室
- - 订阅+
  - 更多科室
工具
服务